Vir Biotechnology vs Xencor
Xencor reported revenue of $126 million in fiscal 2025, 1.8 times Vir Biotechnology's $69 million in fiscal 2025. Vir Biotechnology's revenue fell 7.6% in its latest year, and Xencor's grew 13.7%. Vir Biotechnology had an operating margin of -699.2%, against -141.3% at Xencor. Free cash flow was −$397 million at Vir Biotechnology and −$138 million at Xencor.
Side by side
| Vir Biotechnology | Xencor | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $69M | $126M |
| Revenue growth | −7.6% | 13.7% |
| Revenue growth a year, last 5 years | −2.1% | 0.5% |
| Gross margin | 100.0% | — |
| Operating margin | −699.2% | −141.3% |
| Net margin | −638.9% | −73.2% |
| Free cash flow | −$397M | −$138M |
| Free cash flow margin | −578.5% | −110.1% |
| Return on capital | — | −19.9% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.7% | 14.1% |
| Last close | $12.21 | $35.75 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $8.2 million | sold $3.8 million |
| Piotroski F-score | — | 3 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Vir BiotechnologyXencor
Operating margin
Percent of revenue
Vir BiotechnologyXencor
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Vir BiotechnologyXencor
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Vir Biotechnology and Xencor pages.